METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
First Claim
Patent Images
1. A method for treating a patient with an active pharmaceutical ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone, comprising the steps of;
determining the patient'"'"'s CYP2D6 genotype; and
administering to the patient an effective amount of the active pharmaceutical ingredient, whereby the amount of the active pharmaceutical ingredient is determined based on the patient'"'"'s CYP2D6 genotype.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
-
Citations
37 Claims
-
1. A method for treating a patient with an active pharmaceutical ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone, comprising the steps of;
determining the patient'"'"'s CYP2D6 genotype; and administering to the patient an effective amount of the active pharmaceutical ingredient, whereby the amount of the active pharmaceutical ingredient is determined based on the patient'"'"'s CYP2D6 genotype. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone, comprising the steps of;
-
13. A method for treating a patient who is a CYP2D6 poor metabolizer with a pharmaceutically active ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone, wherein the patient is administered a lower dosage than would be given to an individual who is not a CYP2D6 poor metabolizer.
- View Dependent Claims (14, 15, 16, 17, 18)
-
19. A method of treating a patient with a pharmaceutically active ingredient including at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone comprising the steps of;
determining whether the patient is being administered a CYP2D6 inhibitor; and reducing the dosage of drug if the patient is being administered a CYP2D6 inhibitor. - View Dependent Claims (20, 21)
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone comprising the steps of;
-
22. A method for determining a patient'"'"'s CYP2D6 phenotype comprising the steps of:
-
administering to the patient a quantity of at least one of;
iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone; anddetermining a first concentration of at least one of iloperidone and an iloperidone metabolite in the patient'"'"'s blood. - View Dependent Claims (23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
-
34. A method for determining whether a patient is at risk for prolongation of his or her QTc interval due to administration of at least one of:
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone comprising the steps of;
measuring a first QTc interval; administering to the patient a quantity of at least one of;
iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidonemeasuring a second QTc interval; and comparing the first and second QTc interval. - View Dependent Claims (35, 36, 37)
- iloperidone, a pharmaceutically acceptable salt of iloperidone, an active metabolite of iloperidone, and a pharmaceutically acceptable salt of an active metabolite of iloperidone comprising the steps of;
Specification